Atossa Therapeutics宣布任命Janet R. REA（公共卫生硕士）为公司研发高级副总裁，旨在加速推进(Z)-Endoxifen项目，使其达到关键的监管里程碑。
此次高层人事任命凸显了公司对(Z)-Endoxifen开发项目的重视，该项目正处于关键发展阶段。Janet R. REA将领导研发团队，专注于推动这一重要药物候选项目向前发展，确保其能够顺利通过各项监管要求。
这一人事变动反映了Atossa Therapeutics在推进其核心药物研发管线方面的战略布局，特别是在(Z)-Endoxifen这一潜在重磅药物的开发上投入更多资源和专业人才。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.